PacBio Expects No Instrument Revenue Before Year's End; Shipped Seven Sequencers as of Sept. 15 | GenomeWeb

By Julia Karow

This story was originally published Sept. 23.

Pacific Biosciences earlier this month provided an update on its business and plans in an amended S-1 filing with the Securities and Exchange Commission in connection with its planned initial public offering.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.